This Annual Report contains forward-looking statements, including statements regarding:

• our expectations for future revenue growth;
• projected timetables for regulatory submissions and approvals for, and market introduction of, new products and services in various jurisdictions, including tolevamer, Mozobil, Renvela, rapid tests and new born screening tests,
• our plans and our anticipated timing for pursuing additional indications and next generation versions for our existing products, including Campath MS, Myozyme, Synvisc, Clolar, Thyrogen;
• our plans to seek marketing approvals for our existing products in additional jurisdictions, including Synvisc and Thymoglobulin;
• the timing of, and availability of data from, clinical trials, including for tolevamer, Mozobil, Thymoglobulin, TSH, tasidotin, GC1008, and Sepra spray;
• our global manufacturing expansion plans and expectations for product production;
• the anticipated drivers for future growth of our company and our products, including Renagel and Fabrazyme;
• our ability obtaining Myozyme reimbursement in additional countries; and
• estimates of the potential markets for our products and services.

Words such as "anticipate," "estimate," "project," "intend," "expect," "believe," "should," "may" and similar expressions are intended to identify forward-looking statements. These statements are subject to risks and uncertainties, and our actual results may differ materially from those that are described in this report. These statements are subject to risks and uncertainties, and our actual results may differ materially from those that are described in this report. These risks and uncertainties include:

• our ability to successfully complete preclinical and clinical development of our products;
• our ability to secure regulatory approvals for our products and services and to do so on the anticipated timeframes;
• the content and timing of submissions to and decisions made by the United States Food and Drug Administration, commonly referred to as the FDA, the European Agency for the Evaluation of Medicinal Products, or EMEA, and other regulatory agencies;
• our ability to manufacture sufficient amounts of our products for development and commercialization activities and to do so in a timely and cost-effective manner;
• our reliance on third parties to provide us with materials and services in connection with the manufacture of our products;
• our ability to obtain and maintain adequate patent and other proprietary rights protection for our products and services and successfully enforce our proprietary rights;
• our ability to satisfy the post-marketing commitments made as a condition of the marketing approvals of Fabrazyme, Aldurazyme and Myozyme;
• the availability of reimbursement for our products and services from third party payors, the extent of such coverage and the accuracy of our estimates of the payor mix for our products;
• the scope, validity and enforceability of patents and other proprietary rights held by third parties and their impact on our ability to commercialize our products and services;
• the accuracy of our estimates of the size and characteristics of the markets to be addressed by our products and services, including growth projections;
• market acceptance of our products and services in expanded areas of use and new markets;
• our ability to identify new patients for our products and services;
• our ability to increase market penetration both outside and within the United States for our products and services;
• the accuracy of our information regarding the products and resources of our competitors and potential competitors;
• our ability to effectively manage wholesaler inventories of our products and the levels of compliance with our inventory management programs; and
• our ability to establish and maintain strategic license, collaboration and distribution arrangements and to manage our relationships with licensors, collaborators, distributors and partners.

We have included more detailed descriptions of these and other risks and uncertainties under the heading "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on March 1, 2007. We encourage you to read those descriptions carefully. We caution investors not to place substantial reliance on forward-looking statements. These statements, like all statements in the Annual Report, speak only as of the date of the report (unless another date is indicated) and we undertake no obligation to update or revise the statements. In addition, you should read individual statements appearing in our SEC filings with and in the context of the complete documents in which they appear, and any materials incorporated into those documents by reference, rather than as stand-alone documents.

Historical Information
This is a summary of Genzyme Corporation's Annual Report. Certain information that is included in the Annual Report, including the financial statements and notes thereto, has been omitted. We encourage you to read the full Annual Report and qualify the information in this summary by reference to that filing. This summary is current as of March 1, 2007 and has not been updated to reflect changes in the business of Genzyme after that date. For current press releases, please visit the investors section of www.genzyme.com. For a full printed copy of the Annual Report, please download and print the on-line pdf file or email Genzyme.

Links to Genzyme's Website

Link to Form 10-K

Link to Investors Section

Link to PDF File

corpcom@genzyme.com